Meta title: MOTS-c Legal Status 2026: FDA PCAC
Meta description: MOTS-c legal status 2026: FDA reclassification, PCAC review, compounding pathway, research-only limits and FAQ.
MOTS-c legal status 2026 is now a high-intent search query because FDA’s Pharmacy Compounding Advisory Committee is reviewing MOTS-c during the July 23, 2026 peptide meeting. BioPharma already has a MOTS-c research cluster; this update adds the regulatory layer researchers are actively looking for.
For same-site research catalog context, see MOTS-c research material, BPC-157 research material, and RAD-140 research material.
MOTS-c Legal Status 2026: The Direct Answer
MOTS-c is not FDA approved for human consumption. It was removed from Category 2 in April 2026 and placed into the July 23 PCAC review process for possible 503A authorized bulks-list consideration. That is meaningful, but it is not final compounding authorization.
Exact query: “Is MOTS-c legal in 2026?”
The accurate research-only answer is that MOTS-c is under active FDA advisory review in 2026. A positive PCAC recommendation could move the process forward, but FDA rulemaking would still be required before a clear 503A compounding pathway exists.
MOTS-c FDA Reclassification: What Category 2 Removal Means
FDA’s April 15, 2026 Category 2 removal covered several peptides, including MOTS-c, BPC-157, TB-500, Semax, Epitalon, KPV, DSIP, GHK-Cu, LL-37, Dihexa, PEG-MGF and Melanotan II. Category 2 removal matters because it reverses a restrictive classification, but it does not automatically add MOTS-c to an authorized bulks list.
Exact query: “MOTS-c FDA approved”
MOTS-c is not FDA approved. PCAC review is an advisory step related to compounding policy. It should not be described as approval, treatment authorization, or a green light for human use.
Comparison: MOTS-c Compounding 2026 vs Research Use
| Question | Compounding pathway | Research-only pathway |
|---|---|---|
| Decision maker | FDA rulemaking after advisory input | Researchers and institutions following applicable rules |
| 2026 status | PCAC review; no final 503A authorization yet | Research catalog context with strict non-human-use disclaimers |
| Claims allowed | No disease or human-use claims without approval | Mechanism, model and assay discussion only |
| Practical takeaway | Watch FDA docket and final rulemaking | Document identity, purity, endpoints and compliance boundaries |
Research Evidence Section
- Regulatory evidence: The July 23 Thor report identifies MOTS-c as part of Day 1 PCAC review, alongside BPC-157, KPV and TB-500.
- Category 2 evidence: The same report records April 15, 2026 FDA removal of 12 peptides from Category 2 after February 2026 HHS direction.
- Metabolic evidence: A 2026 J Clin Transl Endocrinol paper reported systemic MOTS-c levels in adults with obesity in association with metabolic dysregulation.
- Microprotein evidence: 2026 pathology research continues to frame mitochondrial-derived microproteins, including MOTS-c, as relevant to cancer and neurodegeneration model questions.
Protocol and Dosage Research Overview
This section is limited to research-design concepts. It does not provide dosage, administration, injection, reconstitution, cycle length, timing, titration or human-use instructions. A compliant MOTS-c research overview should focus on model selection, mitochondrial endpoints, metabolic markers, comparator groups, analytical identity and source documentation.
Legal-status research should also track the difference between advisory votes and final rules. Even a favorable PCAC recommendation would not create a human-use dosage protocol. For research purposes only. Not for human consumption.
FAQ: MOTS-c Legal Status 2026
What is MOTS-c legal status in 2026?
MOTS-c was removed from FDA Category 2 in April 2026 and reviewed by PCAC on July 23, 2026. That does not equal FDA approval or immediate legal compounding; formal rulemaking would still be required.
Is MOTS-c FDA approved?
No. The 2026 PCAC review concerns possible 503A bulks-list consideration, not FDA approval for human consumption or disease treatment.
What does PCAC review mean for MOTS-c research?
A favorable recommendation would be a regulatory signal for future compounding rulemaking, while researchers still need research-only labeling, documentation and compliant claims.
Is MOTS-c for human consumption?
No. For research purposes only. Not for human consumption.
